LY 3143753Alternative Names: LY3143753
Latest Information Update: 23 Jan 2015
At a glance
- Originator Eli Lilly
- Mechanism of Action Glucagon receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypoglycaemia
Most Recent Events
- 01 Jan 2015 Phase-I clinical trials in healthy volunteers in United Kingdom (SC)